Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

idelalisib

Known as: 5-Fluoro-3-phenyl-2-((S)-1-(9H-purin-6-ylamino)-propyl)-3H- quinazolin-4-one, 5-Fluoro-3-phenyl-2-((S)-1-(9H-purin-6-ylamino)-propyl)-3H-quinazolin-4-one, 5-fluoro-3-phenyl-2-[(1S)-1-(3H-purin-6-ylamino)propyl]quinazolin-4(3H)-one 
An orally bioavailable, small molecule inhibitor of the delta isoform of the 110 kDa catalytic subunit of class I phosphoinositide-3 kinase (PI3K… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2019
Review
2019
A multitude of new agents for the treatment of hematologic malignancies has been introduced over the past decade. Hematologists… Expand
Review
2018
Review
2018
BACKGROUND The present review is part of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study… Expand
  • table 1
  • table 2
Review
2018
Review
2018
The importance of the phosphatidylinositol-3-kinase (PI3K) pathway in cell survival and proliferation has made it an attractive… Expand
  • figure 1
  • table 1
  • table 2
Review
2018
Review
2018
On the occasion of its recent approval for relapsed follicular lymphoma, we review the design and development of the pan-class I… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Review
2017
Review
2017
Phosphoinositide 3-kinase (PI3K) activity is stimulated by diverse oncogenes and growth factor receptors, and elevated PI3K… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Highly Cited
2016
Highly Cited
2016
Idelalisib is a small-molecule inhibitor of PI3Kδ with demonstrated efficacy for the treatment of relapsed/refractory chronic… Expand
  • table 1
  • figure 1
  • table 2
  • figure 2
  • figure 3
Highly Cited
2014
Highly Cited
2014
BACKGROUND Patients with relapsed chronic lymphocytic leukemia (CLL) who have clinically significant coexisting medical… Expand
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • table 2
Highly Cited
2014
Highly Cited
2014
BACKGROUND Phosphatidylinositol-3-kinase delta (PI3Kδ) mediates B-cell receptor signaling and microenvironmental support signals… Expand
  • table 1
  • table 1
  • figure 1
  • figure 2
  • figure 3
Highly Cited
2014
Highly Cited
2014
In a phase 1 trial, idelalisib (GS-1101, CAL-101), a selective inhibitor of the lipid kinase PI3Kδ, was evaluated in 54 patients… Expand
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
Highly Cited
2011
Highly Cited
2011
Phosphatidylinositol-3-kinase p110δ serves as a central integration point for signaling from cell surface receptors known to… Expand
  • figure 1
  • figure 2